Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 62

1.

Population-based analysis of breast cancer treatment by intrinsic sub-type in Manitoba, Canada.

Hammond E, Shu E, Sawchuk K, Myal Y, Raouf A, Klonisch T, Hombach-Klonisch S, Leygue E, Kung S, Safneck J, Mowat M, Xu W, Murphy L, Pitz M.

Cancer Epidemiol. 2016 Dec;45:82-90. doi: 10.1016/j.canep.2016.10.006. Epub 2016 Oct 19.

PMID:
27770672
2.

Identification of Claudin 1 Transcript Variants in Human Invasive Breast Cancer.

Blanchard AA, Zelinski T, Xie J, Cooper S, Penner C, Leygue E, Myal Y.

PLoS One. 2016 Sep 20;11(9):e0163387. doi: 10.1371/journal.pone.0163387. eCollection 2016.

3.

Prolactin-Inducible Protein: From Breast Cancer Biomarker to Immune Modulator-Novel Insights from Knockout Mice.

Ihedioha OC, Shiu RP, Uzonna JE, Myal Y.

DNA Cell Biol. 2016 Oct;35(10):537-541. Epub 2016 Sep 7. Review.

PMID:
27602994
4.

Claudin 1 Expression Levels Affect miRNA Dynamics in Human Basal-Like Breast Cancer Cells.

Majer A, Blanchard AA, Medina S, Booth SA, Myal Y.

DNA Cell Biol. 2016 Jul;35(7):328-39. doi: 10.1089/dna.2015.3188. Epub 2016 Mar 16.

PMID:
26982264
5.

Cell-Specific Cre Strains For Genetic Manipulation in Salivary Glands.

Maruyama EO, Aure MH, Xie X, Myal Y, Gan L, Ovitt CE.

PLoS One. 2016 Jan 11;11(1):e0146711. doi: 10.1371/journal.pone.0146711. eCollection 2016.

6.

Claudin 1 in Breast Cancer: New Insights.

Zhou B, Moodie A, Blanchard AA, Leygue E, Myal Y.

J Clin Med. 2015 Nov 27;4(12):1960-76. doi: 10.3390/jcm4121952. Review.

7.

The steroid receptor RNA activator protein (SRAP) controls cancer cell migration/motility.

Yan Y, Cooper C, Hamedani MK, Guppy B, Xu W, Tsuyuki D, Zhang C, Nugent Z, Blanchard A, Davie JR, McManus K, Murphy LC, Myal Y, Leygue E.

FEBS Lett. 2015 Dec 21;589(24 Pt B):4010-8. doi: 10.1016/j.febslet.2015.11.007. Epub 2015 Nov 17.

8.

Claudin 1 promotes migration and increases sensitivity to tamoxifen and anticancer drugs in luminal-like human breast cancer cells MCF7.

Zhou B, Blanchard A, Wang N, Ma X, Han J, Schroedter I, Leygue E, Myal Y.

Cancer Invest. 2015;33(9):429-39. doi: 10.3109/07357907.2015.1060996. Epub 2015 Aug 17.

PMID:
26288115
9.

Claudin 1 Promotes Migration and Increases Sensitivity to Tamoxifen and Anticancer Drugs in Luminal-like Human Breast Cancer Cells MCF7.

Zhou B, Blanchard A, Wang N, Ma X, Han J, Schroedter I, Leygue E, Myal Y.

Cancer Invest. 2015 Aug 17. [Epub ahead of print]

PMID:
26279089
10.

Towards further defining the proteome of mouse saliva.

Blanchard AA, Ezzati P, Shamshurin D, Nistor AC, Leygue E, Wilkins JA, Myal Y.

Proteome Sci. 2015 Feb 25;13:10. doi: 10.1186/s12953-015-0068-3. eCollection 2015.

11.

Sirtuin-3 (SIRT3) Protein Attenuates Doxorubicin-induced Oxidative Stress and Improves Mitochondrial Respiration in H9c2 Cardiomyocytes.

Cheung KG, Cole LK, Xiang B, Chen K, Ma X, Myal Y, Hatch GM, Tong Q, Dolinsky VW.

J Biol Chem. 2015 Apr 24;290(17):10981-93. doi: 10.1074/jbc.M114.607960. Epub 2015 Mar 10.

12.

Deficiency of prolactin-inducible protein leads to impaired Th1 immune response and susceptibility to Leishmania major in mice.

Li J, Liu D, Mou Z, Ihedioha OC, Blanchard A, Jia P, Myal Y, Uzonna JE.

Eur J Immunol. 2015 Apr;45(4):1082-91. doi: 10.1002/eji.201445078. Epub 2015 Feb 12.

13.

Steroid receptor RNA activator protein (SRAP) expression as a prognostic factor in ER+ human breast tumors.

Yan Y, Penner CC, Skliris GP, Cooper C, Nugent Z, Blanchard A, Hamedani MK, Wang X, Myal Y, Murphy LC, Leygue E.

J Cancer Res Clin Oncol. 2013 Oct;139(10):1637-47. doi: 10.1007/s00432-013-1485-2. Epub 2013 Aug 2.

PMID:
23907597
14.

Claudin 1 expression in basal-like breast cancer is related to patient age.

Blanchard AA, Ma X, Dueck KJ, Penner C, Cooper SC, Mulhall D, Murphy LC, Leygue E, Myal Y.

BMC Cancer. 2013 May 30;13:268. doi: 10.1186/1471-2407-13-268.

15.

Expression of both estrogen receptor-beta 1 (ER-β1) and its co-regulator steroid receptor RNA activator protein (SRAP) are predictive for benefit from tamoxifen therapy in patients with estrogen receptor-alpha (ER-α)-negative early breast cancer (EBC).

Yan Y, Li X, Blanchard A, Bramwell VH, Pritchard KI, Tu D, Shepherd L, Myal Y, Penner C, Watson PH, Leygue E, Murphy LC.

Ann Oncol. 2013 Aug;24(8):1986-93. doi: 10.1093/annonc/mdt132. Epub 2013 Apr 11.

PMID:
23579816
16.

Steroid Receptor RNA Activator bi-faceted genetic system: Heads or Tails?

Cooper C, Vincett D, Yan Y, Hamedani MK, Myal Y, Leygue E.

Biochimie. 2011 Nov;93(11):1973-80. doi: 10.1016/j.biochi.2011.07.002. Epub 2011 Jul 12. Review.

PMID:
21771633
17.

Claudin 1 in breast tumorigenesis: revelation of a possible novel "claudin high" subset of breast cancers.

Myal Y, Leygue E, Blanchard AA.

J Biomed Biotechnol. 2010;2010:956897. doi: 10.1155/2010/956897. Epub 2010 May 13.

18.

The steroid receptor RNA activator protein is recruited to promoter regions and acts as a transcriptional repressor.

Chooniedass-Kothari S, Hamedani MK, Auge C, Wang X, Carascossa S, Yan Y, Cooper C, Vincett D, Myal Y, Jalaguier S, Cavailles V, Leygue E.

FEBS Lett. 2010 Jun 3;584(11):2218-24. doi: 10.1016/j.febslet.2010.04.022. Epub 2010 Apr 14.

19.

The protein encoded by the functional steroid receptor RNA activator is a new modulator of ER alpha transcriptional activity.

Chooniedass-Kothari S, Vincett D, Yan Y, Cooper C, Hamedani MK, Myal Y, Leygue E.

FEBS Lett. 2010 Mar 19;584(6):1174-80. doi: 10.1016/j.febslet.2010.02.024. Epub 2010 Feb 11.

20.

Generation and initial characterization of the prolactin-inducible protein (PIP) null mouse: accompanying global changes in gene expression in the submandibular gland.

Blanchard A, Nistor A, Castaneda FE, Martin D, Hicks GG, Amara F, Shiu RP, Myal Y.

Can J Physiol Pharmacol. 2009 Oct;87(10):859-72. doi: 10.1139/Y09-077.

PMID:
20052012

Supplemental Content

Support Center